Furthermore, membrane HER3 was upregulated by tyrosine kinase inhibitor treatment in non-small-cell lung cancer cell lines harboring specific driver mutations, including <i>EGFR</i>-activating mutations, <i>ROS1</i> fusions, and <i>ALK</i> fusions. This evidence concerns the gene EGFR and non-small cell lung carcinoma.